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Conclusions: The decrease of NE veno-arterial difference is a directly assessable
physiologic marker reflecting the effects of RDN with reduced renal NE release from
sympathetic nerves. The current systematic follow-up at 3 and 6 months of our patients
will allow the evaluation for a possible association of the pre-post NE RV-RA with the
BP response.
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Background: Ambulatory blood pressure monitoring (ABPM) is mandatory in every
patient with uncontrolled hypertension. Nighttime blood pressure and non-dipping is
associated with cardiovascular morbidity and mortality. Catheter-based renal sympathetic
denervation (RD) in patients with resistant hypertension has been shown to reduce
sympathetic drive and office blood pressure. The influence of RD on ambulatory blood
pressure (ABPM) has not been studied in details.
Methods: One-hundert patients with resistant hypertension undergoing catheter-based
renal denervation were included in the study. Systolic and diastolic blood pressure
(SBP/DBP) as well as ABPM (SBP/DBP average, SBP/DBP daytime, SBP/DBP
nighttime, heart rate (HR) average) and dipping-pattern were analyzed prior to, and at 3
and 6 months follow-up.
Results: RD reduced office SBP and DBP at 3 and 6 months by 22.9/8.1 mmHg and
26.6/9.3 mmHg (p for all 0.001), respectively. After 3 and 6 months 24-hour average
SBP/DBP was reduced by 8.9/4.9 mmHg (p0.019/0.025) and 11.9.5/6.9 mmHg
(p0.022/0.011), respectively. Average SBP/DBP were lowered at 3 and 6 months
follow-up at daytime by 9.6/5.1 mmHg (p0.010/0.001) and 12.1/8.1 mmHg (p0.001/
0.001) and at nighttime by 6.6/5.8 mmHg (p0.003/0.005) and 11.3/4.7 mmHg
(p0.001/0.001), respectively. Renal denervation also reduced maximum SBP by11.9
mmHg at 3 months and by 14.4 mmHg at 6 months follow-up (p0.009 and 0.006)
whereas maximum DBP was not changed.
Conclusions: Beside significant reductions in office SBP and DBP, RD also reduced
24-hour average, daytime and nighttime SBP and DBP as well as maximum SBP after 3
and 6 months.
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Background: Catheter-based selective renal sympathetic denervation has emerged as a
new therapeutic option for patients with resistant hypertension. Recent studies have shown
that ablation of the renal sympathetic nerves using radiofrequency (RF) energy delivered
from within the renal artery is safe and effective. The OneShot™ device (Covidien,
Campbell, CA) is a balloon-based RF system using a mounted spiral electrode with a
unique feature of irrigation of the vessel lumen during treatment. The non-compliant
balloon is inflated under low pressure (1 atm) in the renal artery. The electrode delivers
RF energy to ablate adjacent nerve bundles with a single 2-minute treatment.
Methods: The RHAS study was a single-center feasibility study performed at Mercy
Hospital in Auckland, New Zealand. Eligible patients had an office systolic blood pressure
(SBP) 160 mmHg (150 if diabetic) despite a drug regimen that included two or more
antihypertensive medications. Renal artery diameters were 4-7mm. The primary endpoint
was the ability to insert the OneShot™ device into each renal artery and deliver RF
energy. Secondary endpoints included office SBP at 6 months.
Results: Nine patients were enrolled; baseline characteristics and outcomes are shown
below. The technical success rate was 88.9%. One failure occurred in the first enrolled
patient and was due to an incorrect software setting which inhibited delivery of RF energy.
All remaining patients had both renal arteries treated with the OneShot™ device. The
mean procedure time (device insertion to end of treatment) was 16 minutes. At 30 days,
the mean office SBP was 155  19 mmHg, a change of 31  14 mmHg. Six-month
results are pending.
Characteristic/Outcome Mean  SD or % (n/N)
Age (yrs) 58.0 15.8
Male gender 55.6% (5/9)
Weight (kg) 84.1 16.5
# Anti-hypertensive meds 3.0 0.7
Serious adverse events 0.0% (0/8)
Office SBP at baseline (mmHg) 186 18
Office SBP at 1 month (mmHg) 155 19
Change from baseline (mmHg) 31 14
Office DBP at baseline (mmHg) 91 14
Office DBP at 1 month (mmHg) 86 14
Change from baseline (mmHg) 6 10
Conclusions: The RHAS trial demonstrated rapid delivery of RF energy for renal
sympathetic denervation using the OneShot™ device with safe blood pressure reduction
at 1 month. Six-month data will be available at time of presentation.
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Background: Catheter-based renal artery denervation therapy has emerged as a novel
therapy in patients with resistant hypertension (HTN). Although initially performed with
a single electrode radiofrequency (RF) catheter, recent advances in catheter designs are
using multiple pre-specified electrode positions. This theoretically could improve the
safety and efficacy of this treatment. We present the 3-month safety and efficacy data from
the international multicenter EnligHTN I trial.
Methods: Inclusion criteria include patients from 18-80 years of age with office systolic
BP 160 mmHg (150 for patients with Type 2 diabetes) on  3 anti HTN agents
(including a diuretic) and renal artery diameter 4mm and length 20mm. Patients with
dual main renal arteries are excluded. The primary end-point is the change in office BP at
6 months from baseline. The safety endpoints include vascular and renal artery
complications. Renal artery CT angiography is performed at baseline and repeated at 6
months. Utilizing femoral artery access with an 8Fr RDC guiding sheath the EnligHTN
catheter is introduced into the renal artery, and RF energy delivered sequentially for 90
seconds per electrode. The catheter is repositioned, rotated and denervation repeated. Both
renal arteries are treated.
Results: In total 46 patients underwent renal denervation. Mean age was 6010
yrs and baseline BP 176/96 mmHg. The median procedure time (from initiation to
completion of RF delivery) was 34.0 min. The mean number of therapies
delivered was 7.7 for the right and 7.4 for the left renal arteries. There was no
change in renal function pre and post procedure (eGFR 76 and 75 mL/min/1.73m2
respectively). There were no renal artery or serious vascular complications
through 3 months. The BP changes pre-discharge and at 1 month were 23/
9(n45, p0.0001) and 28/10 mmHg respectively(n46, p0.0001). The
preliminary 3-month BP change is 37/17 mmHg(n24, p0.0001).
Conclusions: Renal denervation was performed safely and swiftly in patients with
resistant HTN using the EnligHTN catheter. Initial results show a significant early
reduction in BP that continues to reduce further at 3 months.
TCT-214
Abstract Withdrawn
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AM www.jacc.tctabstracts2012.com
B62 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Renal Denervation
P
O
ST
E
R
S
